Voveran SR is a sustained-release formulation of diclofenac sodium, a well-established nonsteroidal anti-inflammatory drug (NSAID) designed for the management of chronic pain and inflammatory conditions. It provides continuous therapeutic plasma levels over a 24-hour period, ensuring consistent symptom control and improved patient compliance. This formulation is particularly indicated for conditions requiring prolonged analgesic and anti-inflammatory effects, such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. By minimizing peak-trough fluctuations, Voveran SR offers a balanced approach to pain management with a reduced dosing frequency.

Features

• Active ingredient: Diclofenac sodium 100 mg
• Pharmaceutical form: Sustained-release tablet
• Mechanism: Cyclooxygenase (COX) inhibition, reducing prostaglandin synthesis
• Release profile: Designed for gradual drug release over 24 hours
• Prescription status: Available only under medical supervision
• Manufacturer: Novartis (or licensed generics, depending on region)

Benefits

• Provides round-the-clock pain relief, reducing the need for frequent dosing.
• Effectively reduces inflammation and associated symptoms like swelling and stiffness.
• Improves mobility and functional capacity in chronic arthritic conditions.
• Minimizes fluctuations in plasma concentration, enhancing tolerability.
• Supports long-term management of degenerative joint diseases.
• May contribute to improved sleep quality by controlling nighttime pain.

Common use

Voveran SR is commonly prescribed for the symptomatic treatment of chronic inflammatory and degenerative forms of rheumatism, including osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. It is also used in the management of acute musculoskeletal disorders such as periarticular conditions (e.g., bursitis, tendinitis), soft-tissue trauma, and postoperative pain where prolonged anti-inflammatory and analgesic effects are desirable. Its sustained-release properties make it suitable for patients requiring consistent pain control to maintain daily activities.

Dosage and direction

The usual adult dose is one tablet (100 mg) once daily, taken whole with a sufficient amount of fluid, preferably with or after food to minimize gastrointestinal irritation. The tablet must not be chewed, crushed, or divided, as this may alter the release kinetics. Dosage adjustment may be necessary in elderly patients or those with hepatic or renal impairment, under strict medical guidance. Treatment should be initiated at the lowest effective dose for the shortest duration possible, consistent with therapeutic goals.

Precautions

Use with caution in patients with a history of gastrointestinal disorders (e.g., ulcers, bleeding), cardiovascular disease, hypertension, renal or hepatic impairment, asthma, or bleeding diatheses. Periodic monitoring of renal function, liver enzymes, and blood pressure is recommended during long-term therapy. Patients should be advised to avoid alcohol and other NSAIDs concurrently. Voveran SR may mask signs of infection; careful diagnosis is essential in febrile illnesses.

Contraindications

Hypersensitivity to diclofenac, other NSAIDs, or any excipients in the formulation. Contraindicated in patients with active peptic ulceration, gastrointestinal bleeding, severe heart failure, ischemic heart disease, peripheral arterial disease, cerebrovascular disease, or severe renal/hepatic impairment. Should not be used during the third trimester of pregnancy or in breastfeeding mothers. Not recommended for use in children.

Possible side effects

Common side effects include gastrointestinal disturbances such as nausea, dyspepsia, abdominal pain, diarrhea, and flatulence. Less frequently, dizziness, headache, skin rash, or elevated liver enzymes may occur. Serious but rare adverse effects include gastrointestinal ulceration or bleeding, cardiovascular events (e.g., myocardial infarction, stroke), renal impairment, hepatitis, and severe skin reactions. Patients should seek immediate medical attention for signs of allergic reactions, chest pain, shortness of breath, weakness on one side of the body, or black stools.

Drug interactions

Voveran SR may interact with anticoagulants (e.g., warfarin), antiplatelet agents, other NSAIDs, corticosteroids, ACE inhibitors, angiotensin II receptor antagonists, diuretics, lithium, methotrexate, cyclosporine, and selective serotonin reuptake inhibitors (SSRIs). Concurrent use may increase the risk of bleeding, nephrotoxicity, or hepatotoxicity. Consult a healthcare provider before combining with any other medication, including over-the-counter products.

Missed dose

If a dose is missed, it should be taken as soon as remembered, unless it is almost time for the next scheduled dose. In that case, skip the missed dose and resume the usual dosing schedule. Do not double the dose to make up for a missed one.

Overdose

Symptoms of overdose may include nausea, vomiting, epigastric pain, gastrointestinal bleeding, drowsiness, dizziness, tinnitus, or convulsions. In severe cases, acute renal failure, respiratory depression, or coma may occur. Management is supportive and symptomatic; there is no specific antidote. Gastric lavage or activated charcoal may be considered if ingestion was recent. Hemodialysis is not effective due to high protein binding.

Storage

Store at room temperature (15–30°C), in a dry place, protected from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.

Disclaimer

This information is for educational purposes only and does not replace professional medical advice. Always consult a qualified healthcare provider for diagnosis, treatment decisions, and personalized recommendations. Do not initiate, discontinue, or change dosage without medical supervision.

Reviews

Clinical studies and patient reports indicate that Voveran SR is effective in providing sustained pain relief and improving quality of life in chronic inflammatory conditions. Many users appreciate the convenience of once-daily dosing and consistent symptom control. However, individual responses may vary, and some patients report gastrointestinal discomfort. Always discuss benefits and risks with your physician.